Inhibitory Effects on Cytochrome P450 Enzymes of Pentamidine and Its Amidoxime Pro-Drug
Anja Bürenheide
Department of Pharmaceutical Chemistry, Pharmaceutical Institute, Christian-Albrechts-University of Kiel, Kiel, Germany
Search for more papers by this authorThomas Kunze
Department of Pharmaceutical Chemistry, Pharmaceutical Institute, Christian-Albrechts-University of Kiel, Kiel, Germany
Search for more papers by this authorBernd Clement
Department of Pharmaceutical Chemistry, Pharmaceutical Institute, Christian-Albrechts-University of Kiel, Kiel, Germany
Search for more papers by this authorAnja Bürenheide
Department of Pharmaceutical Chemistry, Pharmaceutical Institute, Christian-Albrechts-University of Kiel, Kiel, Germany
Search for more papers by this authorThomas Kunze
Department of Pharmaceutical Chemistry, Pharmaceutical Institute, Christian-Albrechts-University of Kiel, Kiel, Germany
Search for more papers by this authorBernd Clement
Department of Pharmaceutical Chemistry, Pharmaceutical Institute, Christian-Albrechts-University of Kiel, Kiel, Germany
Search for more papers by this authorAbstract
Abstract: Pentamidine is an antimicrobial drug, intravenously used in the treatment of trypanosomiasis, leishmaniasis or pneumocystis pneumonia. To elucidate potential drug interactions with pentamidine and N,N′-dihydroxypentamidine, respectively, the cytochrome P450 (CYP450) inhibitory properties of these compounds were determined. The study was performed in vitro by using human liver microsomes and marker substrates of several CYP450 isoenzymes. Marker activities were investigated by high-performance liquid chromatography in presence of known selective inhibitors or at different concentrations of pentamidine and N,N′-dihydroxypentamidine, respectively. No or only minor influence on CYP1A2, 2A6, 2C9, 2C19, 2D6, 2E1 and 3A4 marker activities could be observed, suggesting that neither of the tested substances would exert a significant effect on hepatic CYP450 isoenzymes responsible for the metabolism of co-administrated drugs in vivo. However, in vivo studies are needed before final conclusions can be drawn.
References
- 1 Lourie EM, Yorke W. Studies in chemotherapy. XXI. The trypanocidal action of certain aromatic diamidines. Ann Trop Med Parasitol 1939; 33: 289–304.
- 2 Das BP, Boykin DW. Synthesis and antiprotozoal activity of 2,5-bis(4-guanylphenyl)furans. J Med Chem 1977; 20: 531–6.
- 3 Clement B, Raether W. Amidoximes of pentamidine: synthesis, trypanocidal and leishmanicidal activity. Arzneimittelforschung 1985; 35: 1009–14.
- 4 Bell CA, Hall JE, Kyle DE, Grogl M, Ohemeng KA, Allen MA et al . Structure-activity relationships of analogs of pentamidine against Plasmodium falciparum and Leishmania mexicana amazonensis. Antimicrob Agents Chemother 1990; 34: 1381–6.
- 5 Lindsay DS, Blagburn BL, Hall JE, Tidwell RR. Activity of pentamidine and pentamidine analogs against Toxoplasma gondii in cell cultures. Antimicrob Agents Chemother 1991; 35: 1914–6.
- 6 Pesanti EL, Cox C. Metabolic and synthetic activities of Pneumocystis carinii in vitro. Infect Immun 1981; 34: 908–14.
- 7 Pifer LL, Pifer DD, Woods DR. Biological profile and response to anti-pneumocystis agents of Pneumocystis carinii in cell culture. Antimicrob Agents Chemother 1983; 24: 674–8.
- 8 Berger BJ, Lombardy RJ, Marbury GD, Bell CA, Dykstra CC, Hall JE et al . Metabolic N-hydroxylation of pentamidine in vitro. Antimicrob Agents Chemother 1990a; 34: 1678–84.
- 9 Berger BJ, Reddy VV, Le ST, Lombardy RJ, Hall JE, Tidwell RR. Hydroxylation of pentamidine by rat liver microsomes. J Pharmacol Exp Ther 1991; 256: 883–9.
- 10 Berger BJ, Naiman NA, Hall JE, Peggins J, Brewer TG, Tidwell RR. Primary and secondary metabolism of pentamidine by rats. Antimicrob Agents Chemother 1992; 36: 1825–31.
- 11 Bronner U, Ericsson O, Nordin J, Wikstrom I, Abdi YA, Hall JE et al . Metabolism is an important route of pentamidine elimination in the rat: disposition of 14C-pentamidine and identification of metabolites in urine using liquid chromatography-tandem mass spectrometry. Pharmacol Toxicol 1995; 77: 114–20.
- 12 Clement B, Jung F. N-hydroxylation of the antiprotozoal drug pentamidine catalyzed by rabbit liver cytochrome P450 2C3 or human liver microsomes, microsomal retroreduction, and further oxidative transformation of the formed amidoximes. Possible relationship to the biological oxidation of arginine to NG-hydroxyarginine, citrulline, and nitric oxide. Drug Metab Dispos 1994; 22: 486–97.
- 13 Clement B, Bürenheide A, Rieckert W, Schwarz J. Diacetydiamidoximeester of pentamidine, a prodrug for treatment of protozoal diseases: synthesis, in vitro and in vivo biotransformation. Chem Med Chem 2006; 1: 1260–7.
- 14 Clement B, Immel M, Terlinden R, Wingen FJ. Reduction of amidoxime derivatives to pentamidine in vivo. Arch Pharm (Weinheim) 1992; 325: 61–62.
- 15 Ettmayer P, Amidon GL, Clement B, Testa B. Lessons learned from marketed and investigational prodrugs. J Med Chem 2004; 47: 2393–2404.
- 16 Clement B. Methoden zur Behandlung und Prophylaxe der Pneumocystis carinii Pneumonie (PCP) und anderen Erkrankungen sowie Verbindungen und Formulierungen zum Gebrauch bei besagten Methoden. German patent, P 4321444.4, PCT/DE 94/00756(1994); USA (5, 786, 383;28/6/1998); Europe (0708640, 16/9/1998).
- 17 Clement B, u.a. Verbesserung der Bioverfügbarkeit von Wirkstoffen mit Amidin-funktion in Arzneimitteln, Anmeldetag 21.07.2006, DE 10 2006 034 256.9.
- 18 Kadlubar FF, Ziegler DM. Properties of a NADH-dependent N-hydroxy amine reductase isolated from pig liver microsomes. Arch Biochem Biophys 1974; 162: 83–92.
- 19 Clement B, Lomb R, Moller W. Isolation and characterization of the protein components of the liver microsomal O2-insensitive NADH-benzamidoxime reductase. J Biol Chem 1997; 272: 19615–20.
- 20 Andersson S, Hofmann Y, Nordling A, Li XQ, Nivelius S, Andersson TB et al . Characterization and partial purification of the rat and human enzyme systems active in the reduction of N-hydroxymelagatran and benzamidoxime. Drug Metab Dispos 2005; 33: 570–8.
- 21 Havemeyer A, Bittner F, Wollers S, Mendel R, Kunze T, Clement B. Identification of the missing component in the mitochondrial benzamidoxime prodrug converting system as a novel molybdenum enzyme. J Biol Chem 2006; 281: 34796–802.
- 22 Clement B, Demesmaeker M, Linne S. Microsomal catalyzed N-hydroxylation of guanabenz and reduction of the N-hydroxylated metabolite: characterization of the two reactions and genotoxic potential of guanoxabenz. Chem Res Toxicol 1996; 9: 682–8.
- 23 Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD et al . Measurement of protein using bicinchoninic acid. Anal Biochem 1985; 150: 76–85.
- 24 Omura T, Sato R. The carbon monoxide binding pigment of liver microsomes. J Biol Chem 1964; 239: 2370–8.
- 25 Zebothsen I, Kunze T, Clement B. Inhibitory effects of cytostatically active 6-aminobenzo[c]phenanthridines on cytochrome P450 enzymes in human hepatic microsomes. Basic Clin Pharmacol Toxicol 2006; 99: 37–43.
- 26 Busby WF, Ackermann JM, Crespi CL. Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P450. Drug Metab Dispos 1999; 27: 246–9.
- 27 Chauret N, Gauthier A, Nicoll-Griffith DA. Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. Drug Metab Dispos 1998; 26: 1–4.
- 28 Hickman D, Wang JP, Wang Y, Unadkat JD. Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metab Dispos 1998; 26: 207–15.
- 29 Bapiro TE, Egnell A, Hasler JA, Masimirembra CM. Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos 2001; 29: 30–5.
- 30 White N. Antimalarial drug resistance and combination chemotherapy. Philos Trans R Soc Lond B Biol Sci 1999; 354: 739–49.
- 31 http://www.who.int/topics/leishmaniasis/en/ May 2000.
- 32 Watson J. Pneumocystis carinii: where are we now? J HIV Ther 2002; 7: 8–12.
- 33 Kremers P. Can drug-drug interactions be predicted from in vitro studies? Scientific World Journal 2002; 2: 751–66.
- 34 Committee for Proprietary Medicinal Products. Note for Guidance on the Investigation for Drug Interactions (CPMP/EWP/560/95). The European Agency for Evaluation of Medicinal Products, Human Medicines Evaluation Unit, London, 17 December 1997.
- 35 Wang RW, Newton DJ, Scheri TD, Lu AY. Human cytochrome P450 3A4-catalyzed testosterone 6 beta-hydroxylation and erythromycin N-demethylation. Competition during catalysis. Drug Metab Dispos 1997; 25: 502–7.
- 36 Easterbrook J, Lu C, Sakai Y, Li AP. Effects of organic solvents on the activities of cytochrome P450 isoforms, UDP-dependent glucuronyl transferase, and phenol sulfotransferase in human hepatocytes. Drug Metab Dispos 2001; 29: 141–4.
- 37 Donkor IO, Huang TL, Tao B, Rattendi D, Lane S, Vargas M et al . Trypanocidal activity of conformationally restricted pentamidine congeners. J Med Chem 2003; 46: 1041–8.
- 38 Ismail MA, Brun R, Wenzler T, Tanious FA, Wilson WD, Boykin DW. Dicationic biphenyl benzimidazole derivates as antiprotozoal agents. Bioorg Med Chem 2004; 12: 5405–13.
- 39 Arafa RK, Brun R, Wenzler T, Tanious FA, Wilson WD, Stephens CE et al . Synthesis, DNA affinity, and antiprotozoal activity of fused ring dicationic compounds and their prodrugs. J Med Chem 2005; 48: 5480–8.
- 40 Brendle JJ, Outlaw A, Kumar A, Boykin DW, Patrick DA, Tidwell RR et al . Antileishmanial activities of several classes of aromatic dications. Antimicrob Agents Chemother 2002; 46: 797–807.
- 41 Waalkes TP, Makulu DR. Pharmacologic aspects of pentamidine. Natl Cancer Inst Monogr 1976; 43: 171–7.
- 42 Berger BJ, Hall JE, Tidwell RR. The distribution of multiple doses of pentamidine in rats. Pharmacol Toxicol 1990b; 66: 234–6.
- 43 Wingen F. Autoradiography study of organ distribution of 14C pentamidine following intravenous and inhalational administration in rats. Med Klin (Munich) 1990; 85 (Suppl 2): 236–44.